CALABASAS, California, USA, November 19, 2026
NeOnc Technologies Holdings, Inc. has announced that the U.S. Food and Drug Administration (FDA) has rescheduled its End-of-Phase 1 Type B meeting for NEO212, an investigational oral therapy targeting central nervous system (CNS) cancers, to November 23, 2026. The meeting will focus on the company’s proposed clinical development strategy, including Phase 2 study design, patient selection, endpoints, dose selection, and potential regulatory pathways. The regulatory discussion comes after completion of the Phase 1 dose-escalation portion of the NEO212-01 clinical trial and represents an important planning milestone as NeOnc prepares for the next stages of clinical evaluation. The rescheduling from November 17 to November 23 changes the meeting date but does not indicate FDA endorsement of the proposed trial design or future approval of the investigational drug.
FDA Discussion to Shape Phase 2 Clinical Trial Strategy
The upcoming meeting is intended to provide NeOnc with an opportunity to obtain FDA feedback on the Phase 2a and Phase 2b portions of the NEO212-01 program, including the proposed patient population, study design, clinical endpoints, dose selection, and regulatory development options. The company plans to use the agency’s feedback to inform the continued development of NEO212 for patients with CNS cancers who have limited treatment options. The meeting follows the FDA’s September 2025 authorization for NeOnc to proceed with the Phase 2a and Phase 2b portions of NEO212-01. However, the scheduled regulatory discussion does not establish that the agency has agreed to the company’s proposed development plan, and additional clinical, nonclinical, manufacturing, or regulatory requirements may be identified during the review process.
Phase 1 Dose Escalation Establishes Recommended Dose
The Phase 1 dose-escalation study evaluated NEO212 dosing and identified 610 mg as the recommended Phase 2 dose following a dose-limiting toxicity observed at 810 mg. The higher dose was administered once daily on Days 1 through 5 of a 28-day treatment cycle, after which dose escalation was discontinued. The selection of the recommended Phase 2 dose provides a basis for further clinical evaluation of the investigational therapy, with subsequent studies expected to assess treatment tolerability, clinical activity, and additional safety parameters. Establishing an appropriate dose remains a critical component of oncology drug development, particularly for therapies targeting complex CNS malignancies, where balancing potential antitumor activity with tolerability is important for treatment continuation and patient outcomes.
Early Patient Responses Support Further Investigation
NeOnc has reported preliminary clinical observations from two patients treated during the Phase 1 study. One patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma experienced a partial response, including an approximately 60% reduction in tumor size, with disease control lasting 21 treatment months. A second patient with lung cancer metastatic to the brain, who had previously progressed following multiple treatments, including immune checkpoint inhibitors, experienced stable disease for approximately 16 months while receiving NEO212. These individual patient outcomes provide a clinical rationale for further investigation but do not establish efficacy or predict outcomes across a broader patient population. Larger clinical studies will be necessary to determine the treatment’s safety, efficacy, durability of response, and potential role in CNS cancer treatment. NEO212 remains investigational and has not received regulatory approval. Following receipt of the official FDA meeting minutes, NeOnc expects to host an investor webinar outlining the agency’s feedback and anticipated next steps in the development program.
Source: NeOnc Technologies press release



